Treats serious bacterial infections caused by susceptible strains of the designated…. ANDA 65122, held by Fresenius Kabi USA. Tobramycin Sulfate.
As of Nov 16, 2026, ANDA 65122 (Tobramycin Sulfate), held by Fresenius Kabi USA, was first approved by FDA on Nov 29, 2002, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa, E. coli, and Klebsiella sp. Lower respiratory tract infections caused by P. aeruginos a, Klebsiella sp, Enterobacter sp, Serratia sp, E. coli, and S. aureus (penicillinase- and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella sp, and Enterobacter sp.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 29, 2002 | Original application | Approved | None posted |
| Tobramycin SulfateEQ 10MG BASE/ML · injectable;injection | Tobramycin Sulfate | Rx |
| Tobramycin SulfateEQ 40MG BASE/ML · injectable;injection | Tobramycin Sulfate | Rx |
| Feb 10, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 1, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 1, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 1, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jan 29, 2014 | Supplement 8Labeling · Standard review | Approved | |
| Sep 26, 2005 | Supplement 4Labeling | Approved | None posted |
| Apr 1, 2004 | Supplement 3Labeling | Approved | None posted |
| Nov 29, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters